Director of Islet Cell Biology

  Sigilon Therapeutics is a multidisciplinary biotechnology company which specializes in creating immune privileged products to address unmet clinical needs. Sigilon Therapeutics’s technology has the ability to completely transform how we treat patients with chronic diseases. Originated from Robert Langer and Daniel Anderson’s laboratories of MIT and was patented and published in three seminal reports in Nature Materials, Nature Biotechnology, and Nature Medicine in 2015 and 2016. The company is based in Cambridge, MA and is funded by Flagship Pioneering. Now is the time to get in on the ground floor of a fast growing company with a very interactive and open culture. Please forward your application via email to

Sigilon Therapeutics is searching for an energized candidate to help develop and execute on a program focused on allogeneic stem-cell derived pancreatic islet cells for treatment of diabetes. We seek a senior level scientist who is an expert in islet cell biology to further the work on this important therapy. Expertise in beta cell differentiation from hESC or iPSC cells is a critical aspect of the position.